Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms

References

• Muscogiuri G, Altieri B, Albertelli M, et al. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020;69(2):441–450.
   PubMed Web of Science ®Google Scholar
• Ruggeri RM, Benevento E, De Cicco F, et al. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. J Endocrinol Invest. 2023;46(2):213–234.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• Modica R, Liccardi A, Minotta R, et al. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab. 2022;17(5):389–403.
   PubMed Web of Science ®Google Scholar
• Faggiano A, Di Maio S, Mocerino C, et al. Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019;66(2):417–424.
   PubMed Web of Science ®Google Scholar
• Faggiano A, Lo Calzo F, Pizza G, et al. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017;16(10):1149–1161.
   PubMed Web of Science ®Google Scholar
• Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–154. doi: 10.1007/s12022-022-09708-2
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Guadagno E, Messina E, et al. Open issues on G3 neuroendocrine neoplasms: back to the future. Endocr Relat Cancer. 2018;25(6):R375–R384.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–2686.
   PubMed Web of Science ®Google Scholar
• Altieri B, Di Dato C, Martini C, et al. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers (Basel). 2019;11(9):11.
   Web of Science ®Google Scholar
• Kečkéš Š, Palaj J, Waczulíková I, et al. Pretreatment levels of chromogranin a and neuron-specific enolase in patients with gastroenteropancreatic neuroendocrine neoplasia. In Vivo. 2021;35(5):2863–2868.
   PubMed Web of Science ®Google Scholar
• Modica R, Benevento E, Colao A. Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship. J Endocrinol Invest. 2023;46(4):667–677. doi: 10.1007/s40618-022-01983-4
   PubMed Web of Science ®Google Scholar
• Modica R, La Salvia A, Liccardi A, et al. Lipid metabolism and homeostasis in patients with neuroendocrine neoplasms: from risk factor to potential therapeutic target. Metabolites. 2022;12(11):12.
   Web of Science ®Google Scholar
• Feola T, Puliani G, Sesti F, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case–control study. J Endocrinol Invest. 2022;45(4):849–857.
   PubMed Web of Science ®Google Scholar
• Colao A, de Nigris F, Modica R, et al. Clinical epigenetics of neuroendocrine tumors: the road ahead. Front Endocrinol. 2020;11:604341. doi: 10.3389/fendo.2020.604341
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.
   PubMed Web of Science ®Google Scholar
• von Arx C, Capozzi M, López-Jiménez E, et al. Updates on the role of molecular alterations and NOTCH signalling in the development of neuroendocrine neoplasms. J Clin Med. 2019;8(9):1277.
   PubMed Web of Science ®Google Scholar
• Barrea L, Muscogiuri G, Modica R, et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol. 2021;12:649496. doi: 10.3389/fendo.2021.649496
   PubMed Web of Science ®Google Scholar
• Altieri B, Di Dato C, Modica R, et al. Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. Nutrients. 2020;12(4):12.
   Web of Science ®Google Scholar
• Vanoli A, La Rosa S, Luinetti O, et al. Histologic changes in type a chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum Pathol. 2013;44(9):1827–1837. doi: 10.1016/j.humpath.2013.02.005
   PubMed Web of Science ®Google Scholar
• Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes. 2009;16(1):72–78. doi: 10.1097/MED.0b013e328320d845
   PubMedGoogle Scholar
• Das S, Dasari A. Epidemiology, incidence, and prevalence of Neuroendocrine Neoplasms: are there global differences? Curr Oncol Rep. 2021;23:43. doi: 10.1007/s11912-021-01029-7
   PubMed Web of Science ®Google Scholar
• Rindi G, Inzani F, Solcia E. Pathology of gastrointestinal disorders. Endocrinol Metab Clin North Am. 2010;39(4):713–727. doi: 10.1016/j.ecl.2010.08.009
   PubMed Web of Science ®Google Scholar
• Sei Y, Feng J, Samsel L, et al. Mature enteroendocrine cells contribute to basal and pathological stem cell dynamics in the small intestine. Am J Physiol Gastrointest Liver Physiol. 2018;315(4):G495–G510. doi: 10.1152/ajpgi.00036.2018
   PubMed Web of Science ®Google Scholar
• Asa SL, La Rosa S, Basturk O, et al. Molecular pathology of well-differentiated gastro-entero-pancreatic neuroendocrine tumors. Endocr Pathol. 2021;32(1):169–191. doi: 10.1007/s12022-021-09662-5
   PubMed Web of Science ®Google Scholar
• Banck MS, Kanwar R, Kulkarni AA, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013;123(6):2502–2508.
   PubMed Web of Science ®Google Scholar
• Cunningham JL, Díaz de Ståhl T, Sjöblom T, et al. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer. 2011;50(2):82–94.
   PubMed Web of Science ®Google Scholar
• Choi I-S, Estecio MRH, Nagano Y, et al. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007;20(7):802–810.
   PubMed Web of Science ®Google Scholar
• Stricker I, Tzivras D, Nambiar S, et al. Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours. Anticancer Res. 2012;32(9):3699–3706.
   PubMed Web of Science ®Google Scholar
• How-Kit A, Dejeux E, Dousset B, et al. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors. Epigenomics. 2015;7(8):1245–1258.
   PubMed Web of Science ®Google Scholar
• Edfeldt K, Ahmad T, Åkerström G, et al. TCEB3C a putative tumor suppressor gene of small intestinal neuroendocrine tumors. Endocr Relat Cancer. 2014;21(2):275–284.
   PubMed Web of Science ®Google Scholar
• Zhang H-Y, Rumilla KM, Jin L, et al. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. Endocrine. 2006;30(3):299–306.
   PubMed Web of Science ®Google Scholar
• Ruebel K, Leontovich AA, Stilling GA, et al. MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol. 2010;23(3):367–375.
   PubMed Web of Science ®Google Scholar
• Li S-C, Essaghir A, Martijn C, et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol. 2013;26(5):685–696.
   PubMed Web of Science ®Google Scholar
• Karpathakis A, Dibra H, Pipinikas C, et al. Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res. 2016;22(1):250–258.
   PubMed Web of Science ®Google Scholar
• Cross AJ, Leitzmann MF, Subar AF, et al. A prospective study of meat and fat intake in relation to small intestinal cancer. Cancer Res. 2008;68(22):9274–9279.
   PubMed Web of Science ®Google Scholar
• Klöppel G, Anlauf M, Perren A, et al. Hyperplasia to neoplasia sequence of duodenal and pancreatic neuroendocrine diseases and pseudohyperplasia of the PP-cells in the pancreas. Endocr Pathol. 2014;25(2):181–185.
   PubMed Web of Science ®Google Scholar
• Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30(5):560–574.
   PubMed Web of Science ®Google Scholar
• Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med. 1990;322(11):723–727.
   PubMed Web of Science ®Google Scholar
• Vortmeyer AO, Huang S, Lubensky I, et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89(4):1934–1938. doi: 10.1210/jc.2003-031575
   PubMed Web of Science ®Google Scholar
• Perren A, Anlauf M, Henopp T, et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab. 2007;92(3):1118–1128.
   PubMed Web of Science ®Google Scholar
• Pea A, Hruban RH, Wood LD. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol. 2015;9(11):1407–1419. doi: 10.1586/17474124.2015.1092383
   PubMed Web of Science ®Google Scholar
• Ohmoto A, Rokutan H, Yachida S. Pancreatic neuroendocrine neoplasms: basic biology, Current treatment strategies and prospects for the future. Int J Mol Sci. 2017;18(1):18. doi: 10.3390/ijms18010143
   Web of Science ®Google Scholar
• de Wilde RF, Heaphy CM, Maitra A, et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol. 2012;25(7):1033–1039.
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28(2):245–255.
   PubMed Web of Science ®Google Scholar
• La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67(11):938–948. doi: 10.1136/jclinpath-2014-202515
   PubMed Web of Science ®Google Scholar
• La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42(10):1373–1384.
   PubMed Web of Science ®Google Scholar
• La Rosa S, Solcia E. New insights into the classification of gastric neuroendocrine tumours, expanding the spectrum of ECL-cell tumours related to hypergastrinaemia. Histopathology. 2020;77(6):862–864. doi: 10.1111/his.14226
   PubMed Web of Science ®Google Scholar
• Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41(4):185–200.
   PubMed Web of Science ®Google Scholar
• Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol. 2001;13(12):1449–1456.
   PubMed Web of Science ®Google Scholar
• Toh B-H, Chan J, Kyaw T, et al. Cutting edge issues in autoimmune gastritis. Clin Rev Allergy Immunol. 2012;42(3):269–278.
   PubMed Web of Science ®Google Scholar
• Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis—pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529–541.
   PubMed Web of Science ®Google Scholar
• Whittingham S, Mackay IR. Autoimmune gastritis: historical antecedents, outstanding discoveries, and unresolved problems. Int Rev Immunol. 2005;24(1–2):1–29. doi: 10.1080/08830180590884413
   PubMed Web of Science ®Google Scholar
• Lahner E, Centanni M, Agnello G, et al. Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med. 2008;121(2):136–141.
   PubMed Web of Science ®Google Scholar
• Rugge M, Fassan M, Pizzi M, et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther. 2012;35(12):1460–1466.
   PubMed Web of Science ®Google Scholar
• Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33(12):1361–1369.
   PubMed Web of Science ®Google Scholar
• Calvete O, Reyes J, Zuñiga S, et al. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Hum Mol Genet. 2015;24(10):2914–2922.
   PubMed Web of Science ®Google Scholar
• Solcia E, Capella C, Fiocca R, et al. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol. 1990;14(6):503–513.
   PubMed Web of Science ®Google Scholar
• Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168–172.
   PubMed Web of Science ®Google Scholar
• Abraham SC, Carney JA, Ooi A, et al. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol. 2005;29(7):969–975.
   PubMed Web of Science ®Google Scholar
• Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93(5):1582–1591.
   PubMed Web of Science ®Google Scholar
• Trinh V-H, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020;77(6):865–876. doi: 10.1111/his.14220
   PubMed Web of Science ®Google Scholar
• Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014; CD010623. doi: 10.1002/14651858.CD010623.pub2
   PubMed Web of Science ®Google Scholar
• Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012;36(7):644–649.
   PubMed Web of Science ®Google Scholar
• Cavalcoli F, Zilli A, Conte D, et al. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence? Scand J Gastroenterol. 2015;50(11):1397–1403.
   PubMed Web of Science ®Google Scholar
• Haga Y, Nakatsura T, Shibata Y, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci. 1998;43(2):253–257.
   PubMed Web of Science ®Google Scholar
• Lahner E, Pilozzi E, Esposito G, et al. Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge. Scand J Gastroenterol. 2014;49(4):506–510.
   PubMed Web of Science ®Google Scholar
• Nandy N, Hanson JA, Strickland RG, et al. Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literature. Dig Dis Sci. 2016;61(3):708–712.
   PubMed Web of Science ®Google Scholar
• Milione M, Parente P, Grillo F, et al. Neuroendocrine neoplasms of the duodenum, ampullary region, jejunum and ileum. Pathologica. 2021;113(1):12–18.
   PubMed Web of Science ®Google Scholar
• Vinik AI, McLeod MK, Fig LM, et al. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am. 1989;18(4):865–896.
   PubMed Web of Science ®Google Scholar
• Burke AP, Sobin LH, Federspiel BH, et al. Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases. Arch Pathol Lab Med. 1990;114(7):700–704.
   PubMed Web of Science ®Google Scholar
• Anlauf M, Enosawa T, Henopp T, et al. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol. 2008;32(7):1101–1105.
   PubMed Web of Science ®Google Scholar
• Mete O, Asa SL. Precursor lesions of endocrine system neoplasms. Pathology. 2013;45(3):316–330. doi: 10.1097/PAT.0b013e32835f45c5
   PubMed Web of Science ®Google Scholar
• Anlauf M, Perren A, Klöppel G. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology. 2007;74(5):279–284. doi: 10.1159/000105810
   PubMed Web of Science ®Google Scholar
• Mpilla G, Aboukameel A, Muqbil I, et al. PAK4-NAMPT dual inhibition as a novel strategy for therapy resistant pancreatic neuroendocrine tumors. Cancers (Basel). 2019;11(12):11.
   Web of Science ®Google Scholar
• Holle GE, Spann W, Eisenmenger W, et al. Diffuse somatostatin-immunoreactive D-cell hyperplasia in the stomach and duodenum. Gastroenterology. 1986;91(3):733–739.
   PubMed Web of Science ®Google Scholar
• Mastracci L, Rindi G, Grillo F, et al. Neuroendocrine neoplasms of the esophagus and stomach. Pathologica. 2021;113(1):5–11.
   PubMed Web of Science ®Google Scholar
• Giannetta E, Guarnotta V, Rota F, et al. A rare rarity: neuroendocrine tumor of the esophagus. Crit Rev Oncol Hematol. 2019;137:92–107. doi: 10.1016/j.critrevonc.2019.02.012
   PubMed Web of Science ®Google Scholar
• Hoang MP, Hobbs CM, Sobin LH, et al. Carcinoid tumor of the esophagus: a clinicopathologic study of four cases. Am J Surg Pathol. 2002;26(4):517–522.
   PubMed Web of Science ®Google Scholar
• Cai W, Ge W, Yuan Y, et al. A 10-year population-based study of the differences between NECs and carcinomas of the esophagus in terms of clinicopathology and survival. J Cancer. 2019;10(6):1520–1527.
   PubMed Web of Science ®Google Scholar
• Konishi T, Watanabe T, Kishimoto J, et al. Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut. 2007;56(6):863–868.
   PubMed Web of Science ®Google Scholar
• Volante M, Grillo F, Massa F, et al. Neuroendocrine neoplasms of the appendix, colon and rectum. Pathologica. 2021;113(1):19–27.
   PubMed Web of Science ®Google Scholar
• Yu J, Refsum E, Perrin V, et al. Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel. Ann Oncol. 2022;33(6):649–656.
   PubMed Web of Science ®Google Scholar
• Derikx LAAP, Vierdag W-M, Kievit W, et al. Is the prevalence of colonic neuroendocrine tumors increased in patients with inflammatory bowel disease? Int J Cancer. 2016;139(3):535–542.
   PubMed Web of Science ®Google Scholar
• Moyana TN, Satkunam N. A comparative immunohistochemical study of jejunoileal and appendiceal carcinoids. Implications for histogenesis and pathogenesis. Cancer. 1992;70(5):1081–1088. doi: 10.1002/1097-0142(19920901)70:5<1081:AID-CNCR2820700512>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Nascimbeni R, Villanacci V, Di Fabio F, et al. Solitary microcarcinoid of the rectal stump in ulcerative colitis. Neuroendocrinology. 2005;81(6):400–404.
   PubMed Web of Science ®Google Scholar
• Lyss AP. Appendiceal malignancies. Semin Oncol. 1988;15(2):129–137.
   PubMed Web of Science ®Google Scholar
• Pape U-F, Niederle B, Costa F, et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology. 2016;103(2):144–152.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer. 1968;21(2):270–278. doi: 10.1002/1097-0142(196802)21:2<270:AID-CNCR2820210217>3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Auböck L, Höfler H. Extraepithelial intraneural endocrine cells as starting-points for gastrointestinal carcinoids. Virchows Arch A Pathol Anat Histopathol. Virchows Arch A Pathological Anatomy Histopathol. 1983;401(1):17–33. doi: 10.1007/BF00644786
   PubMedGoogle Scholar
• Papadaki L, Rode J, Dhillon AP, et al. Fine structure of a neuroendocrine complex in the mucosa of the appendix. Gastroenterology. 1983;84(3):490–497.
   PubMed Web of Science ®Google Scholar
• Sesia SB, Mayr J, Bruder E, et al. Neurogenic appendicopathy: clinical, macroscopic, and histopathological presentation in pediatric patients. Eur J Pediatr Surg. 2013;23(3):238–242.
   PubMed Web of Science ®Google Scholar
• Karkouche R, Bachet J-B, Sandrini J, et al. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol. 2012;24(12):1430–1437.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–2823.
   PubMed Web of Science ®Google Scholar
• Ikegame K, Hatakeyama K, Terashima M, et al. Molecular profiling of gastric neuroendocrine carcinomas. Eur J Surg Oncol. 2023;49(9):106987.
   PubMed Web of Science ®Google Scholar
• Venizelos A, Elvebakken H, Perren A, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2021;29(1):1–14.
   PubMed Web of Science ®Google Scholar
• Idrees K, Padmanabhan C, Liu E, et al. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol. 2018;117(2):284–289.
   PubMed Web of Science ®Google Scholar
• Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–184.
   PubMed Web of Science ®Google Scholar
• Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.
   PubMed Web of Science ®Google Scholar
• Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83.
   PubMed Web of Science ®Google Scholar
• Grassia R, Bodini P, Dizioli P, et al. Neuroendocrine carcinomas arising in ulcerative colitis: coincidences or possible correlations? World J Gastroenterol. 2009;15(33):4193–4195.
   PubMed Web of Science ®Google Scholar
• Bolzacchini E, Chini C, Cortelezzi CC, et al. Poorly differentiated neuroendocrine carcinoma of the sigmoid tract in long-standing ulcerative colitis: report of a case and review of the literature. Int J Surg Pathol. 2018;26(5):479–483.
   PubMed Web of Science ®Google Scholar
• Sigel JE, Goldblum JR. Neuroendocrine neoplasms arising in inflammatory bowel disease: a report of 14 cases. Mod Pathol. 1998;11(6):537–542.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, Pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–1242.
   PubMed Web of Science ®Google Scholar
• McGuire AL, Maziak DE, Sekhon HS. Diffuse intrapulmonary neuroendocrine cell hyperplasia. Can Respir J. 2013;20(6):406–408. doi: 10.1155/2013/190409
   PubMed Web of Science ®Google Scholar
• Rossi G, Cavazza A, Spagnolo P, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. Eur Respir J. 2016;47(6):1829–1841.
   PubMed Web of Science ®Google Scholar
• Rea F, Rizzardi G, Zuin A, et al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg. 2007;31(2):186–191.
   PubMed Web of Science ®Google Scholar
• Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22(8):934–944.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191–199.
   PubMed Web of Science ®Google Scholar
• Dingemans A-M, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(7):839–853.
   PubMed Web of Science ®Google Scholar
• Onuki N, Wistuba IIR, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999;85(3):600–607.
   PubMed Web of Science ®Google Scholar
• Alì G, Boldrini L, Capodanno A, et al. Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med. 2011;2(5):787–792.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Furukawa KT, Morimoto M. Pulmonary neuroendocrine cells: physiology, tissue homeostasis and disease. Dis Model Mech. 2020;13(12):13. doi: 10.1242/dmm.046920
   Web of Science ®Google Scholar
• Fu XW, Spindel ER. Recruitment of GABA(A) receptors in chemoreceptor pulmonary neuroepithelial bodies by prenatal nicotine exposure in monkey lung. Adv Exp Med Biol. 2009;648:439–445.
   PubMed Web of Science ®Google Scholar
• Fu XW, Nurse CA, Wong V, et al. Hypoxia-induced secretion of serotonin from intact pulmonary neuroepithelial bodies in neonatal rabbit. J Physiol. 2002;539(2):503–510.
   PubMed Web of Science ®Google Scholar
• Hajiasgharzadeh K, Sadigh-Eteghad S, Mansoori B, et al. Alpha7 nicotinic acetylcholine receptors in lung inflammation and carcinogenesis: Friends or foes? J Cell Physiol. 2019;234(9):14666–14679.
   PubMed Web of Science ®Google Scholar
• Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies. Int J Cancer. 2012;131(5):1210–1219.
   PubMed Web of Science ®Google Scholar
• Varghese AM, Zakowski MF, Yu HA, et al. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014;9(6):892–896.
   PubMed Web of Science ®Google Scholar
• Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-Mutant lung Cancers at risk for Histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784–1793.
   PubMed Web of Science ®Google Scholar
• Xiong W-M, Xu Q-P, Li X, et al. The association between human papillomavirus infection and lung cancer: a system review and meta-analysis. Oncotarget. 2017;8(56):96419–96432.
   PubMedGoogle Scholar
• Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022;35:36–50. doi: 10.1038/s41379-021-00943-2
   PubMed Web of Science ®Google Scholar
• Borczuk AC. Pulmonary Neuroendocrine Tumors. Surg Pathol Clin. 2020;13(1):35–55. doi: 10.1016/j.path.2019.10.002
   PubMedGoogle Scholar
• Modlin IM, Kidd M, Filosso P-L, et al. Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms. J Thorac Dis. 2017;9(S15):S1458–S1473.
   PubMedGoogle Scholar
• Bohnenberger H, Ströbel P. Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus. Virchows Arch. 2021;478(1):129–135. doi: 10.1007/s00428-021-03037-1
   PubMed Web of Science ®Google Scholar
• Ströbel P, Zettl A, Shilo K, et al. Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study. Genes Chromosomes Cancer. 2014;53(9):738–749.
   PubMed Web of Science ®Google Scholar
• Dinter H, Bohnenberger H, Beck J, et al. Molecular classification of neuroendocrine tumors of the thymus. J Thorac Oncol. 2019;14(8):1472–1483.
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35. doi: 10.1016/j.cell.2012.03.003
   PubMed Web of Science ®Google Scholar
• Teh BT, Zedenius J, Kytölä S, et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg. 1998;228(1):99–105.
   PubMed Web of Science ®Google Scholar
• Gibril F, Chen Y-J, Schrump DS, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2003;88(3):1066–1081.
   PubMed Web of Science ®Google Scholar
• Cowen T, Thrasivoulou C, Shaw SA, et al. Transplanted sweat glands from mature and aged donors determine cholinergic phenotype and altered density of host sympathetic nerves. J Auton Nerv Syst. 1996;58(3):153–162.
   PubMedGoogle Scholar
• Wong LH, McGhie JD, Sim M, et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res. 2010;20(3):351–360.
   PubMed Web of Science ®Google Scholar
• Liu R, Wang W, Ye L, et al. p21-activated kinase 3 is overexpressed in thymic neuroendocrine tumors (carcinoids) with ectopic ACTH syndrome and participates in cell migration. Endocrine. 2010;38(1):38–47.
   PubMed Web of Science ®Google Scholar
• Bi Y, Liu R, Ye L, et al. Gene expression profiles of thymic neuroendocrine tumors (carcinoids) with ectopic ACTH syndrome reveal novel molecular mechanism. Endocr Relat Cancer. 2009;16(4):1273–1282.
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science. 1995;268(5208):225–232. doi: 10.1126/science.7716513
   PubMed Web of Science ®Google Scholar
• Xavier-Junior JCC, Ocanha‐Xavier JP, Xavier-Junior JCCO-X JP. WHO (2018). Classification of skin tumors. Am J Dermatopathol. 2019;41(9):699–700. doi: 10.1097/DAD.0000000000001446
   Web of Science ®Google Scholar
• Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3(1):17077.
   PubMedGoogle Scholar
• Schadendorf D, Lebbé C, Zur Hausen A, et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53–69. doi: 10.1016/j.ejca.2016.10.022
   PubMed Web of Science ®Google Scholar
• Park SY, Doolittle-Amieva C, Moshiri Y, et al. How we treat Merkel cell carcinoma: within and beyond current guidelines. Future Oncol. 2021;17(11):1363–1377.
   PubMed Web of Science ®Google Scholar
• DeCaprio JA. Molecular pathogenesis of Merkel cell carcinoma. Annu Rev Pathol. 2021;16(1):69–91. doi: 10.1146/annurev-pathmechdis-012419-032817
   PubMedGoogle Scholar
• Pietropaolo V, Prezioso C, Moens U. Merkel Cell Polyomavirus and Merkel Cell Carcinoma. Cancers (Basel). 2020;12(7):12. doi: 10.3390/cancers12071774
   Web of Science ®Google Scholar
• Wong SQ, Waldeck K, Vergara IA, et al. UV-Associated mutations underlie the etiology of MCV-Negative Merkel cell carcinomas. Cancer Res. 2015;75(24):5228–5234.
   PubMed Web of Science ®Google Scholar
• Cheng J, Park DE, Berrios C, et al. Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLOS Pathog. 2017;13(10):e1006668.
   PubMed Web of Science ®Google Scholar
• Wells SA, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid: Offic J Am Thyroid Association. 2015;25(6):567–610.
   PubMed Web of Science ®Google Scholar
• Pavlidis E, Sapalidis K, Chatzinikolaou F, et al. Medullary thyroid cancer: molecular factors, management and treatment. Rom J Morphol Embryol. 2020;61(3):681–686.
   PubMed Web of Science ®Google Scholar
• Bongarzone I. RET genetic screening in patients with medullary thyroid cancer: an update. Front Endocrinol (Lausanne). 2020;11:571205. & FL.
   Google Scholar
• Frank-Raue K. Hereditary medullary thyroid carcinoma: current state of knowledge and future perspectives. Eur J Endocrinol. 2021;185(3): R119–R132. BS, & RF.
   Google Scholar
• Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192–202. doi: 10.1038/nrendo.2016.11
   PubMed Web of Science ®Google Scholar
• Kondo T. Aspects of the pathogenesis of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2018;47(3): 481–493. & ES.
   Google Scholar
• Machens A, Lorenz K, Sekulla C, et al. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol. 2013;168(3):307–314.
   PubMed Web of Science ®Google Scholar
• Ciampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience. 2019;20:324–336. doi: 10.1016/j.isci.2019.09.030
   PubMed Web of Science ®Google Scholar
• Wang N, Kjellin H, Sofiadis A, et al. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget. 2016;7(16):21332–21346.
   PubMedGoogle Scholar
• Abraham D, Jackson N, Gundara JS, et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res. 2011;17(14):4772–4781.
   PubMed Web of Science ®Google Scholar
• Ceolin L, Goularte APP, Ferreira CV, et al. Global DNA methylation profile in medullary thyroid cancer patients. Exp Mol Pathol. 2018;105(1):110–114.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s–6249s. doi: 10.1158/1078-0432.CCR-06-0931
   PubMed Web of Science ®Google Scholar
• Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80:1546–1556.
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res. 2006;66(23):11089–11093. doi: 10.1158/0008-5472.CAN-06-2407
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342. doi: 10.1038/nature01658
   PubMed Web of Science ®Google Scholar
• Shupp AB, Kolb AD, Mukhopadhyay D, et al. Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel). 2018;10(6):10.
   PubMed Web of Science ®Google Scholar
• Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis Independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res. 2005;65(23):11001–11009.
   PubMed Web of Science ®Google Scholar
• Cives M, Quaresmini D, Rizzo FM, et al. Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro. Oncotarget. 2017;8(14):22534–22549.
   PubMedGoogle Scholar
• Pusceddu S, Prinzi N, Tafuto S, et al. Association of Upfront Peptide receptor radionuclide therapy with progression-free survival Among patients with enteropancreatic neuroendocrine tumors. JAMA Netw Open. 2022;5(2):e220290.
   PubMed Web of Science ®Google Scholar
• Lania A, Ferraù F, Rubino M, et al. Neoadjuvant therapy for Neuroendocrine Neoplasms: recent progresses and future approaches. Front Endocrinol. 2021;12:651438. doi: 10.3389/fendo.2021.651438
   PubMed Web of Science ®Google Scholar
• Albertelli M, Dotto A, Di Dato C, et al. PRRT: identikit of the perfect patient. Rev Endocr Metab Disord. 2021;22(3):563–579.
   PubMed Web of Science ®Google Scholar
• Massironi S, Campana D, Pusceddu S, et al. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: data from a retrospective multi-centric study. Dig Liver Dis. 2021;53(3):367–374.
   PubMedGoogle Scholar
• Ravindranathan D, Master VA, Bilen MA. Inflammatory markers in Cancer immunotherapy. Biology. 2021;10(4):10. doi: 10.3390/biology10040325
   Google Scholar
• Scandurra C, Modica R, Maldonato NM, et al. Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience. J Clin Endocrinol Metab. 2021;106(1):e316–e327.
   PubMed Web of Science ®Google Scholar